Vetoquinol

Founded in 1933 in Lure, France, Vetoquinol is one of the few independent, family-controlled groups operating at scale in the global veterinary pharmaceuticals market. The company focuses exclusively on animal health, developing and commercialising medicines, vaccines, and nutritional supplements for companion animals and livestock across more than 100 countries.

Vetoquinol is listed on Euronext Paris and operates its own manufacturing sites alongside a broad international commercial presence, with subsidiaries across Europe, North America, South America, Asia, and Oceania. Its companion animal portfolio spans analgesics, anti-infectives, dermatology, and cardiology products, while its food-producing animal range covers cattle, swine, and poultry health. The group invests consistently in research and development, directing a meaningful share of revenue into pipeline innovation each year.

A distinctive aspect of Vetoquinol's strategy is its dual focus on prescription veterinary medicines and over-the-counter nutritional and hygiene products, allowing the group to serve practising veterinarians as well as retail and farm-supply channels. The Zylkene brand, a widely recognised supplement for stress management in cats and dogs, illustrates the company's strength in science-backed nutraceuticals alongside regulated pharmaceuticals.

Further information is available at vetoquinol.com.